Nelson, Charles A.

Clinical Study of Non-Invasive EEG for Children Ages 2-7

FRAXA Research Foundation 2017 Grants • 2018 Grants • 2019 Grants • 2020 Grants • 2021 Grants • Biomarkers • Boston Children's Hospital • Clinical • Clinical Trials • Current Research Grants • Has Results • Nelson, Charles A. • Recruiting • Research Updates • Wilkinson, Carol March 5, 2021March 10, 2021amyloid precursor protein, autism, EEG, Pierce Family Fragile X Foundation, sound

Dr. Carol Wilkinson, MD PhD, and Dr. Charles Nelson, PhD, at Boston Children’s Hospital are recruiting children ages 2-7 years with Fragile X syndrome to participate in a study of brain differences using non-invasive EEG.

Use of EEG as a Biomarker for Diagnosis and Outcomes in Neurodevelopmental Disorders

FRAXA Research Foundation Nelson, Charles A. • Seminar Series • Wilkinson, Carol October 21, 2020amyloid precursor protein, autism, education, EEG, Rett syndrome, TAT (Trans-Activator of Transcription)

A series webinars focused on current topics in Fragile X research featuring Charles A. Nelson III, PhD, Professor at Harvard Medical School and Carol Wilkinson, MD, PhD, Instructor at Boston Children’s Hospital.

Neural Markers of Fragile X: A Powerful New Tool for Clinical Trials

J. Dora Levin Biomarkers • Boston Children's Hospital • Clinical • Harvard University • Nelson, Charles A. • Research Updates • Wilkinson, Carol August 17, 2017June 20, 2019amyloid precursor protein, Autifony Therapeutics, autism, EEG, hypersensitivity, ion channel, Pierce Family Fragile X Foundation, seizure, sleep, sound, TAT (Trans-Activator of Transcription)

Once the neural marker is identified for a particular challenge, such as kids with poor language versus good language, neural markers can be measured during drug and behavioral therapy trials to see if a child is improving based on objective biological measures.